• Je něco špatně v tomto záznamu ?

The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

L. Holubec, J. Polivka, M. Safanda, M. Karas, V. Liska,

. 2016 ; 36 (9) : 4421-6.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013531

Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013531
003      
CZ-PrNML
005      
20171213084202.0
007      
ta
008      
170413s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.10985 $2 doi
035    __
$a (PubMed)27630277
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Holubec, Luboš, $d 1972- $7 xx0068645 $u Biomedical Center, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic.
245    14
$a The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment / $c L. Holubec, J. Polivka, M. Safanda, M. Karas, V. Liska,
520    9_
$a Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a karcinom $x farmakoterapie $x imunologie $7 D002277
650    _2
$a cetuximab $x terapeutické užití $7 D000068818
650    _2
$a kolorektální nádory $x farmakoterapie $x imunologie $7 D015179
650    _2
$a lidé $7 D006801
650    _2
$a imunitní systém $7 D007107
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a erbB receptory $x imunologie $7 D066246
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Polivka, Jiri $u Biomedical Center, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic Department of Histology and Embryology, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic polivkajiri@gmail.com.
700    1_
$a Safanda, Martin $u Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Karas, Michal $u Department of Haematology and Oncology, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 36, č. 9 (2016), s. 4421-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27630277 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20171213084350 $b ABA008
999    __
$a ok $b bmc $g 1199996 $s 974309
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 36 $c 9 $d 4421-6 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20170413
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace